Compile Data Set for Download or QSAR
maximum 50k data
Found 19
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM10484(US11091471, Example RO-301 | US8846719, 301)
Affinity DataKi:  0.200nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM513334(US11091471, Example RE-B)
Affinity DataKi:  0.400nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM133580(US11091471, Example RO-272 | US8846719, 272)
Affinity DataKi:  1nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM133559(US11091471, Example RO-251 | US8846719, 251)
Affinity DataKi:  1nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM513332(US11091471, Example RO-094)
Affinity DataKi:  2.90nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM133472(US11091471, Example RO-159 | US8846719, 159)
Affinity DataKi:  28nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM513333(US11091471, Example RE-A)
Affinity DataKi:  65nMAssay Description:Electrophysiological experiments were performed on days 3 to 5 after the micro-injection of mRNA. During the experiment the oocytes were constantly s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50423736(CHEMBL591543)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141986(US8927534, 262)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141990(US8927534, 266)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141994(US8927534, 269)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141981(US8927534, 120)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141973(US8927534, 114 | US8927534, 83)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141979(US8927534, 75)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141978(US8927534, 29)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141976(US8927534, 23)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141975(US8927534, 20)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50423721(CHEMBL595105)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM141972(US8927534, 11)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent